Cancer Epidemiology

项目总结 癌症流行病学项目 莫菲特癌症中心(Moffitt)癌症流行病学(CE)计划的目标是减轻癌症负担 通过更好地了解暴露、其生物标记和潜在机制，并将 学习知识，为临床和公共卫生实践的进步提供信息。CE计划成员使用稳健 方法学和分析方法，结合了广泛的生物标志物和综合方法来 进行人群水平的研究，为癌症的病因提供信息，同时认识到 在这组不同的疾病中存在异质性。CE项目的创新研究跨越了 从癌症风险到拦截和早期发现再到癌症结果的连续统一体，涵盖了原发、 二级和三级预防，重点是那些严重影响Moffitt‘s的癌症 集水区。行政长官成员致力于将他们的研究成果转化为临床或公众的变化 卫生实践和政策，并转变癌症预防和治疗模式。为达致这些目标，行政长官 项目研究被组织成三个具体目标： 目标1：发现癌症风险的遗传易感标记，确定它们的功能，并利用这一点 精准预防的信息。 目的2：识别和验证非遗传暴露及其影响肿瘤发展的生物标志物， 进展和结果，并利用这些知识来开发可操作的癌症预防策略。 目的3：探讨影响肿瘤早期发现、进展、发展的肿瘤特征及癌前状态。 和结果，并利用这些发现提供新的临床方法。 CE项目由来自8个学术部门的26名教职员工组成。同行评审资金为660万美元 每年的直接成本，其中360万美元来自NCI。这反映了16笔相当于R01/R01的赠款。成员已发表 905篇与癌症相关的学术文章(123篇高影响；影响因子为10)。行政长官成员举行10次同行评议 MPI奖，自2016年以来已累计2371名参与者参加干预试验。科学调查引领 成员们帮助增进了对生物因素的了解--包括普通药物；人类 乳头状瘤病毒、艾滋病毒和其他病毒；基因多态；和放射基因组特征-多发性 癌症是莫菲特集水区死亡率和发病率的主要贡献者。值得注意的是，翻译 CE成员的影响包括HPV疫苗接种政策的变化，对卵巢和 乳腺癌基因检测结果和黑色素瘤倾向基因检测方案指南的改变 家人。CE成员目前还参与前列腺癌和肺癌、阿司匹林等的化学预防试验 卵巢癌的试验，肺癌和胰腺癌的放射基因组学特征，以及鉴定种族- 前列腺癌中特定基因表达谱对临床和公众健康的影响。

PROJECT SUMMARY CANCER EPIDEMIOLOGY PROGRAM The goal of the Moffitt Cancer Center (Moffitt) Cancer Epidemiology (CE) Program is to reduce cancer burden through better knowledge of exposures, their biological markers, and underlying mechanisms, and to translate learned knowledge to inform advances in clinical and public health practice. CE Program Members use robust methodologic and analytic approaches that incorporate a broad array of biomarkers and integrative methods to conduct population-level research that informs the etiology of cancer while recognizing the many aspects of heterogeneity in this diverse group of diseases. The innovative research of the CE Program extends across the cancer continuum from cancer risk to interception and early detection to cancer outcomes covering primary, secondary, and tertiary prevention, with an intentional focus on those cancers that heavily impact Moffitt’s catchment area. CE Members strive to translate their research findings to inform change in clinical or public health practice and policy, and to shift cancer prevention and treatment paradigms. To achieve these goals, CE Program research is organized into three Specific Aims: Aim 1: To discover inherited susceptibility markers of cancer risk, determine their function, and leverage this information for precision prevention. Aim 2: To identify and validate non-genetic exposures and their biomarkers affecting tumor development, progression, and outcome, and use this knowledge to develop actionable cancer prevention strategies. Aim 3: To investigate features of tumors and premalignant conditions that influence early detection, progression, and outcomes and capitalize on these findings to inform novel clinical approaches. The CE Program consists of 26 faculty from eight academic departments. Peer-reviewed funding is $6.6M in annual direct costs, with $3.6M from the NCI. This reflects 16 R01/R01-equivalent grants. Members published 905 cancer-relevant scholarly articles (123 high impact; impact factor ³ 10). CE Members hold 10 peer-reviewed MPI awards and have accrued 2,371 participants onto intervention trials since 2016. Scientific investigations led by Members have helped advance knowledge of biological factors – including common medicines; human papilloma virus, HIV, and other viruses; genetic polymorphisms; and radiogenomic signatures – for multiple cancers that are major contributors to mortality and morbidity in Moffitt’s catchment area. Notably, translational impact of CE Members includes changes in HPV-vaccination policy, updates for the interpretation of ovarian and breast cancer genetic testing results, and guideline changes for genetic testing protocols for melanoma-prone families. CE Members also are currently engaged in chemoprevention trials in prostate and lung cancer, aspirin trials in ovarian cancer, developing radiogenomic signatures in lung and pancreatic cancer, and identifying race- specific gene expression profiles in prostate cancer to impact clinical and public health.